Keywords: Biogen Idec, Icahn, Board members
Biogen Idec receives “notice of intention” from Icahn to nominate three more directors
Article | 29 January 2010
US biopharmaceutical firm Biogen Idec says it has received notice from Icahn Partners and certain of its affiliates of their intention to nominate three individuals to its board of directors.
The three nominees - basically proposed by billionaire Carl Icahn in his third proxy fight with Biogen – are: Eric Rowinsky, a former chief medical officer of ImClone Systems ( company acquired by Eli Lilly in 2008 for nearly $6 billion); Thomas Deuel, a former board member at ImClone; and Richard Young, a researcher at the Massachusetts Institute of Technology. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
